Acepodia
英屬開曼群島商育世博(股)公司
Acepodia is a Taiwan Emerging Stock Board biotechnology company; its most advanced asset is ACE1831 (Phase 1 / Phase 2; recruiting, IgG4 Related Disease), as of 2026-11-01.
Pipeline
| Asset | Target / mechanism | Stage | Indication | Region | Source date | Source |
|---|---|---|---|---|---|---|
| ACE1831 | — | Phase 1 / Phase 2; recruiting | IgG4 Related Disease | China, Japan, United States | 2026-10-02 | Trial registry |
| ACE2016 | — | Phase 1; recruiting | Locally Advanced Solid Tumor; Metastatic Solid Tumor | Taiwan, United States | 2025-07-01 | Trial registry |
| ACE723 | — | Phase 1; not yet recruiting | Hepatocellular Carcinoma (HCC); Hepatocellular Carcinoma Metastatic; Hepatocellular Carcinoma Non-Resectable | China | 2026-10-06 | Trial registry |
Key events
No verified events in the past twelve months.
Related Drugnews articles
No related articles in this language.